Skip to main
ANIX

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences is well-positioned in the immuno-oncology space, with both its cancer prevention and treatment approaches showing promising results. The ongoing Phase 1 trials for its breast cancer vaccine and lira-cel therapies have shown positive signals, supporting continued clinical advancement and investor interest. Additionally, their unique mechanism of using chimeric endocrine receptor T cell (CER-T) technology and targeting the follicle stimulating hormone receptor (FSHR) sets them apart from conventional CAR-T therapies and may offer a more targeted and potentially less toxic approach.

Bears say

Anixa Biosciences is set to participate in the Water Tower Research Insights Conference on April 14, where they are expected to showcase positive Phase 1 data from their breast cancer vaccine and encouraging survival signals from their ovarian cancer CAR-T program. However, despite this early momentum, the company's legacy operations and limited patent licensing activities do not generate significant revenue. Additionally, with only one program currently in clinical trials, there may be limited diversity in their pipeline and success may be heavily dependent on the success of lira-cel.

ANIX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANIX has a Strong Buy consensus rating as of Jul 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.